Literature DB >> 22616664

High frequency of overlap between functional dyspepsia and overactive bladder.

J Matsuzaki1, H Suzuki, Y Fukushima, K Hirata, S Fukuhara, S Okada, T Hibi.   

Abstract

BACKGROUND: Overactive bladder syndrome (OAB) is defined as a symptom complex comprising urgency, with or without urge incontinence, and usually frequency and nocturia. The association between irritable bowel syndrome (IBS) and bladder symptoms has been reported. This study is designed to investigate whether functional dyspepsia (FD), like IBS, is associated with OAB.
METHODS: A web surveys containing questions about OAB, FD, IBS, and demographics were completed by 5494 public individuals (2302 men and 3192 women) who have no history of severe illness. The prevalence and overlap of OAB, FD, and IBS were examined. KEY
RESULTS: Among participants with FD, 20.5% could also be diagnosed with OAB (odds ratio [OR]: 2.85; 95% confidence interval [CI]: 2.21-3.67). Although concomitant FD and IBS were more strongly associated with OAB (OR: 4.34; 95% CI: 2.81-6.73), OAB was also highly prevalent among participants with FD but without IBS (OR: 3.09; 95% CI: 2.29-4.18). Among participants with FD, an overlapping OAB condition was more prevalent in those with both postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) (OR: 3.75; 95% CI: 2.48-5.67) than in those with PDS or EPS alone. Among participants with OAB, the severity of bladder symptoms was greater in participants with dyspeptic symptoms than without them. CONCLUSIONS & INFERENCES: Overactive bladder syndrome is common among FD patients, even if they do not have IBS. To improve FD patients' quality of life, it will be important to provide management for OAB.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22616664     DOI: 10.1111/j.1365-2982.2012.01939.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  14 in total

Review 1.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

2.  The challenges of evolving Rome criteria for functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

3.  Saam Acupuncture for Treating Functional Dyspepsia: A Feasibility Randomized Controlled Trial.

Authors:  Boram Lee; O-Jin Kwon; Joo-Hee Kim; Jung Won Kang; Tae-Hun Kim; Seunghoon Lee; Jungeun Kim; Ae-Ran Kim; So Young Jung; Hyo-Ju Park; Sun-Mi Choi
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

4.  Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.

Authors:  Yasushi Fukushima; Hidekazu Suzuki; Juntaro Matsuzaki; Arihiro Kiyosue; Toshifumi Hibi
Journal:  J Neurogastroenterol Motil       Date:  2012-07-10       Impact factor: 4.924

Review 5.  Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria.

Authors:  Jan Tack; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-12       Impact factor: 46.802

6.  Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Hidekazu Suzuki; Hiroaki Kusunoki; Takeshi Kamiya; Seiji Futagami; Yasuharu Yamaguchi; Toshihiro Nishizawa; Eisuke Iwasaki; Juntaro Matsuzaki; Shinichi Takahashi; Choitsu Sakamoto; Ken Haruma; Takashi Joh; Keiko Asakura; Toshifumi Hibi
Journal:  United European Gastroenterol J       Date:  2013-12       Impact factor: 4.623

7.  Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria.

Authors:  H Vanheel; F Carbone; L Valvekens; M Simren; H Tornblom; T Vanuytsel; L Van Oudenhove; J Tack
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

Review 8.  The incidence of erectile dysfunction after pelvic fracture urethral injury: A systematic review and meta-analysis.

Authors:  Sarah D Blaschko; Melissa T Sanford; Bruce J Schlomer; Amjad Alwaal; Glen Yang; Jacqueline D Villalta; Hunter Wessells; Jack W McAninch; Benjamin N Breyer
Journal:  Arab J Urol       Date:  2014-10-16

9.  Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?: Author's Reply.

Authors:  Hidekazu Suzuki; Juntaro Matsuzaki
Journal:  J Neurogastroenterol Motil       Date:  2012-10-09       Impact factor: 4.924

10.  Burden of impaired sleep quality on work productivity in functional dyspepsia.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Koji Togawa; Tsuyoshi Yamane; Hideki Mori; Takahiro Komori; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-08-07       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.